Cost-Effectiveness of Fidaxomicin for Clostridium difficile Treatment

被引：2
|
作者：
Simon, Matthew S. [1 ,2 ]
机构：
[1] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA
[2] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY 10065 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2014年 / 58卷 / 04期
关键词：
VANCOMYCIN; INFECTION; CANCER;
D O I：
10.1093/cid/cit772
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada
    Wagner, Monika
    Lavoie, Louis
    Goetghebeur, Mireille
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2014, 25 (02) : 87 - 94
  • [42] A scoring system for prescribing fidaxomicin in Clostridium difficile infection
    Jesus Vivancos-Gallego, Maria
    Angeles Jimenez-Lopez, M.
    Gioia, Francesca
    Ibanez-Segura, Dione
    Romero-Vivas, Jose
    Cobo, Javier
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2018, 36 (01): : 34 - 37
  • [43] Fidaxomicin: A guide to its use in Clostridium difficile infection
    Lesley J. Scott
    Katherine A. Lyseng-Williamson
    Sean T. Duggan
    Drugs & Therapy Perspectives, 2012, 28 (6) : 1 - 5
  • [44] Fidaxomicin: A Macrocyclic Antibiotic for the Management of Clostridium difficile Infection
    Sullivan, Karyn M.
    Spooner, Linda M.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (02) : 352 - 359
  • [45] A hospital-level cost-effectiveness analysis model for toxigenic Clostridium difficile detection algorithms
    Verhoye, E.
    Vandecandelaere, P.
    De Beenhouwer, H.
    Coppens, G.
    Cartuyvels, R.
    Van den Abeele, A.
    Frans, J.
    Laffut, W.
    JOURNAL OF HOSPITAL INFECTION, 2015, 91 (02) : 123 - 128
  • [46] Recurrent Clostridium difficile colitis in elderly: the role of fidaxomicin
    Artom, Francesco
    Del Bono, Valerio
    CLINICAL MANAGEMENT ISSUES, 2014, 8 : 13 - 16
  • [47] Safety and Efficacy of Fidaxomicin in Patients With Clostridium Difficile Infection
    Donnelley, Monica A.
    Duby, Jeremiah J.
    Cocanour, Christine S.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2013, 5 : 75 - 79
  • [48] Recommendations from a panel of experts on the usefulness of fidaxomicin for the treatment of infections caused by Clostridium difficile
    Bouza, Emilio
    Cobo, Javier
    Almirante, Benito
    Duenas, Carlos
    Escudero, Rosa
    Farinas, Carmen
    Feher, Csaba
    Pablo Horcajada, Juan
    Merino, Esperanza
    Merino, Paloma
    Montejo, Miguel
    Olmedo, Maria
    Ramos-Martinez, Antonio
    Rodriguez-Pardo, Dolors
    Ruiz Mesa, Juan Diego
    Salavert, Miguel
    Sarria, Cristina
    Tiago Silva, Jose
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2019, 32 (01) : 50 - 59
  • [49] Cost-effectiveness analysis of oral probiotics for the prevention of Clostridium difficile-associated diarrhoea in children and adolescents
    Li, N.
    Zheng, B.
    Cai, H-F
    Chen, Y-H
    Qiu, M-Q
    Liu, M-B
    JOURNAL OF HOSPITAL INFECTION, 2018, 99 (04) : 469 - 474
  • [50] Fidaxomicin Inhibits Clostridium difficile Toxin A-Mediated Enteritis in the Mouse Ileum
    Koon, Hon Wai
    Ho, Samantha
    Hing, Tressia C.
    Cheng, Michelle
    Chen, Xinhua
    Ichikawa, Yoshi
    Kelly, Ciaran P.
    Pothoulakis, Charalabos
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (08) : 4642 - 4650
12345